Published: 14 February 2022
Author(s): Marco Vitolo, Vincenzo L. Malavasi, Marco Proietti, Igor Diemberger, Laurent Fauchier, Francisco Marin, Michael Nabauer, Tatjana S. Potpara, Gheorghe-Andrei Dan, Zbigniew Kalarus, Luigi Tavazzi, Aldo Pietro Maggioni, Deirdre A. Lane, Gregory Y.H. Lip, Giuseppe Boriani, ESC-EHRA EORP-AF Long-Term General Registry Investigators
Issue: May 2022
Section: Original article

Cardiac troponins (cTn) are the preferred biomarkers for the detection of myocardial injury and the diagnosis of myocardial infarction (MI) [1–3]. However, with the advent of high-sensitivity (hs)-cTn assays, elevated levels of cTn may be a common finding in daily clinical practice even in several non-ischaemic, acute or chronic conditions, such as heart failure (HF), chronic kidney disease (CKD), sepsis, inflammatory diseases, etc. [4–10].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.